Trimetazidine inhibits pressure overload-induced cardiac fibrosis through NADPH oxidase-ROS-CTGF pathway

Cardiovascular Research

Volumn 88, Issue 1, 2010, Pages 150-158

  Liu, Xuehui ^a   Gai, Yingli ^a,b   Liu, Fei ^a   Gao, Wei ^a   Zhang, Youyi ^a   Xu, Ming ^a   Li, Zhaoping ^a  

^a PEKING UNIVERSITY   (China)

^b Beijing University of Aeronautics and Astronautics   (China)

Author keywords

Cardiac fibrosis; Connective tissue growth factor; NADPH oxidase; Reactive oxygen species; Trimetazidine

Indexed keywords

ANGIOTENSIN II; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; RAC1 PROTEIN; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TRIMETAZIDINE;

ANIMAL CELL; AORTA CONSTRICTION; ARTICLE; CONTROLLED STUDY; FIBROBLAST; HEART FAILURE; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SHAM PROCEDURE; SIGNAL TRANSDUCTION;

ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; CARDIOMEGALY; CELL PROLIFERATION; CELLS, CULTURED; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FIBROBLASTS; FIBROSIS; HYPERTENSION; MALE; MALONDIALDEHYDE; MYOCARDIUM; NADPH OXIDASE; RAC1 GTP-BINDING PROTEIN; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION; TIME FACTORS; TRIMETAZIDINE; VASODILATOR AGENTS;

EID: 77956816714     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvq181     Document Type: Article

References (41)

1. Weber KT, Brilla CG, Janicki JS. Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res 1993;27:341-348.
2. Yamamoto K, Masuyama T, Sakata Y, Nishikawa N, Mano T, Yoshida J et al. Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovasc Res 2002;55:76-82.
3. Hein S, Arnon E, Kostin S, Schonburg M, Elsasser A, Polyakova V et al. Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 2003;107: 984-991.
4. Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000; 86:580-588.
5. Lopaschuk GD, Barr R, Thomas PD, Dyck JR. Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase. Circ Res 2003;93:e33-e37.
6. Drake-Holland AJ, Belcher PR, Hynd J, Noble MI. Infarct size in rabbits: a modified method illustrated by the effects of propranolol and trimetazidine. Basic Res Cardiol 1993;88:250-258.
7. Fantini E, Demaison L, Sentex E, Grynberg A, Athias P. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reox-ygenation. J Mol Cell Cardiol 1994;26:949-958.
8. Belardinelli R, Solenghi M, Volpe L, Purcaro A. Trimetazidine improves endothelial dysfunction in chronic heart failure: an antioxidant effect. Eur Heart J 2007;28: 1102-1108.
9. Faure JP, Baumert H, Han Z, Goujon JM, Favreau F, Dutheil D et al. Evidence for a protective role of trimetazidine during cold ischemia: targeting inflammation and nephron mass. Biochem Pharmacol 2003;66:2241-2250.
10. Kay L, Finelli C, Aussedat J, Guarnieri C, Rossi A. Improvement of long-term preservation of the isolated arrested rat heart by trimetazidine: effects on the energy state and mitochondrial function. Am J Cardiol 1995;76:45B-49B.
11. Belardinelli R, Purcaro A. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardio-myopathy. Eur Heart J 2001;22:2164-2170.
12. Fragasso G, Palloshi A, Puccetti P, Silipigni C, Rossodivita A, Pala M et al. A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. J Am Coll Cardiol 2006;48:992-998.
13. Fragasso G, Perseghin G, De Cobelli F, Esposito A, Palloshi A, Lattuada G et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phospho-creatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J 2006;27:942-948.
14. Fragasso G, Piatti Md PM, Monti L, Palloshi A, Setola E, Puccetti P et al. Short-and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J 2003;146:E18.
15. Vitale C, Wajngaten M, Sposato B, Gebara O, Rossini P, Fini M et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 2004;25:1814-1821.
16. Tuunanen H, Engblom E, Naum A, Nagren K, Scheinin M, Hesse B et al. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated car-diomyopathy. Circulation 2008;118:1250-1258.
17. Ahmed MS, Oie E, Vinge LE, Yndestad A, Oystein Andersen G, Andersson Y et al. Connective tissue growth factor\a novel mediator of angiotensin II-stimulated cardiac fibroblast activation in heart failure in rats. J Mol Cell Cardiol 2004;36:393-404.
18. Grotendorst GR, Duncan MR. Individual domains of connective tissue growth factor regulate fibroblast proliferation and myofibroblast differentiation. FASEB J 2005;19: 729-738.
19. Koitabashi N, Arai M, Kogure S, Niwano K, Watanabe A, Aoki Y et al. Increased connective tissue growth factor relative to brain natriuretic peptide as a determinant of myocardial fibrosis. Hypertension 2007;49:1120-1127.
20. Iwanciw D, Rehm M, Porst M, Goppelt-Struebe M. Induction of connective tissue growth factor by angiotensin II: integration of signaling pathways. Arterioscler Thromb Vasc Biol 2003;23:1782-1787.
21. Black SA Jr, Palamakumbura AH, Stan M, Trackman PC. Tissue-specific mechanisms for CCN2/CTGF persistence in fibrotic gingiva: interactions between cAMP and MAPK signaling pathways, and prostaglandin E2-EP3 receptor mediated activation of the c-JUN N-terminal kinase. J Biol Chem 2007;282:15416-15429.
22. Ruperez M, Lorenzo O, Blanco-Colio LM, Esteban V, Egido J, Ruiz-Ortega M. Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis. Circulation 2003;108:1499-1505. (Pubitemid 37176458)
23. Pantos C, Bescond-Jacquet A, Tzeis S, Paizis I, Mourouzis I, Moraitis P et al. Trimeta-zidine protects isolated rat hearts against ischemia-reperfusion injury in an experimental timing-dependent manner. Basic Res Cardiol 2005;100:154-160.
24. Bertomeu-Gonzalez V, Bouzas-Mosquera A, Kaski JC. Role of trimetazidine in management of ischemic cardiomyopathy. Am J Cardiol 2006;98:19J-24J.
25. 2+ handling in isoprenaline-mediated myocardial injury of rats. Exp Physiol 2006;91: 591-601.
26. Liao W, Wang S, Han C, Zhang Y. 14-3-3 proteins regulate glycogen synthase 3beta phosphorylation and inhibit cardiomyocyte hypertrophy. FEBS J 2005;272: 1845-1854.
27. Du J, Guan T, Zhang H, Xia Y, Liu F, Zhang Y. Inhibitory crosstalk between ERK and AMPK in the growth and proliferation of cardiac fibroblasts. Biochem Biophys Res Commun 2008;368:402-407.
28. Gong K, Li Z, Xu M, Du J, Lv Z, Zhang Y. A novel protein kinase A-independent, beta-arrestin-1-dependent signaling pathway for p38 mitogen-activated protein kinase activation by beta2-adrenergic receptors. J Biol Chem 2008;283: 29028-29036.
29. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994;74:1141-1148.
30. Takimoto E, Champion HC, Li M, Ren S, Rodriguez ER, Tavazzi B et al. Oxidant stress from nitric oxide synthase-3 uncoupling stimulates cardiac pathologic remodeling from chronic pressure load. J Clin Invest 2005;115:1221-1231.
31. Kai H, Mori T, Tokuda K, Takayama N, Tahara N, Takemiya K et al. Pressure overload-induced transient oxidative stress mediates perivascular inflammation and cardiac fibrosis through angiotensin II. Hypertens Res 2006;29:711-718.
32. Uechi M, Tanaka Y, Aramaki Y, Hori Y, Ishikawa Y, Ebisawa T et al. Evaluation of the renin-angiotensin system in cardiac tissues of cats with pressure-overload cardiac hypertrophy. Am J Vet Res 2008;69:343-348.
33. Koitabashi N, Arai M, Niwano K, Watanabe A, Endoh M, Suguta M et al. Plasma connective tissue growth factor is a novel potential biomarker of cardiac dysfunction in patients with chronic heart failure. Eur J Heart Fail 2008;10:373-379.
34. Grotendorst GR, Okochi H, Hayashi N. A novel transforming growth factor beta response element controls the expression of the connective tissue growth factor gene. Cell Growth Differ 1996;7:469-480.
35. Kutala VK, Khan M, Mandal R, Ganesan LP, Tridandapani S, Kalai T et al. Attenuation of myocardial ischemia-reperfusion injury by trimetazidine derivatives functionalized with antioxidant properties. J Pharmacol Exp Ther 2006;317:921-928.
36. Leivonen SK, Hakkinen L, Liu D, Kahari VM. Smad3 and extracellular signal-regulated kinase 1/2 coordinately mediate transforming growth factor-beta-induced expression of connective tissue growth factor in human fibroblasts. J Invest Dermatol 2005;124: 1162-1169.
37. Iskesen I, Saribulbul O, Cerrahoglu M, Var A, Nazli Y, Sirin H. Trimetazidine reduces oxidative stress in cardiac surgery. Circ J 2006;70:1169-1173.
38. Guarnieri C, Muscari C. Effect of trimetazidine on mitochondrial function and oxi-dative damage during reperfusion of ischemic hypertrophied rat myocardium. Pharmacology 1993;46:324-331.
39. Nakagami H, Takemoto M, Liao JK. NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy. J Mol Cell Cardiol 2003;35:851-859.
40. Zafari AM, Ushio-Fukai M, Akers M, Yin Q, Shah A, Harrison DG et al. Role of NADH/NADPH oxidase-derived H2O2 in angiotensin II-induced vascular hypertrophy. Hypertension 1998;32:488-495.
41. Kheradmand F, Werner E, Tremble P, Symons M, Werb Z. Role of Rac1 and oxygen radicals in collagenase-1 expression induced by cell shape change. Science 1998;280: 898-902.